Monument Therapeutics and the Foundation for the National Institutes of Health (FNIH) will evaluate MT1988, in development for cognitive impairment associated with schizophrenia, in a proof-of-principle clinical trial. Many individuals begin to show signs of schizophrenia months or even years before receiving a diagnosis, referred to as the ‘clinical high risk’ (CHR) phase. The randomised, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!